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ABSTRACT
Treatment-resistant major depression (TRMD, 
major depressive disorder that fails to respond 
to numerous therapies) is a relatively common 
and clinically challenging disorder. In many cases, 
the most severely affected TRMD patients have 
received surgical intervention (subcaudate trac-
totomy, limbic leucotomy, anterior capsulotomy, 
and anterior cingulotomy). New treatments, includ-
ing vagus nerve stimulation (VNS) and deep brain 
stimulation, have emerged to treat individuals 
with TRMD. We describe the case of a woman, 53 
years of age, with a long and sustained history 
of TRMD (33 years), which was unresponsive to 
numerous treatments (multiple pharmacothera-
pies, psychotherapy, electroconvulsive therapy 
[ECT]). Additionally, her TRMD failed to respond 
to a bilateral anterior cingulotomy. She underwent 
placement of a cervical vagus nerve stimulator 
and a brief course of ECT (3 unilateral treatments). 
FOCUS POINTS
•  New, more invasive, treatments, (eg, vagus 
nerve stimulation [VNS], deep brain stimulation), 
are evolving for the treatment of refractory ill-
nesses in psychiatry. 
•  VNS is Food and  Drug Administration approved 
for treatment augmentation in severe, treat-
ment-refractory depression. Studies suggest that 
the antidepressant effects of VNS are typically 
delayed by months.
•  Studies demonstrate that electroconvulsive ther-
apy (ECT) and VNS can be safely administered 
at the same time. Clinical experience and case 
reports suggest that ECT and VNS may have 
synergistic effects, (ie, patients who responded 
poorly to ECT in the past may respond better to 
this treatment after VNS implantation).
Her depression improved markedly, and it has 
remained in sustained remission for 3.5 years. 
This case suggests a potential synergistic effect of 
VNS and ECT, as well as provides possible clues to 
the neural circuitry of VNS in TRMD. 
doi:  10.1017/S1092852912000 0
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INTRODUCTION 
Treatment-resistant major depression (TRMD) is 
a variation of major depressive disorder in which 
patients fail to respond to numerous treatments 
(typically antidepressants with augmentation strat-
egies and psychotherapy).1 In many patients with 
TRMD, a variety of treatments, delivered singly or 
in combination, including pharmacotherapies, psy-
chotherapies, and electroconvulsive therapy (ECT), 
fail to provide an adequate response. Psychiatry 
has begun to explore more invasive treatments 
for TRMD, including vagus nerve stimulation 
(VNS),2 which was approved by the Food and Drug 
Administration as an adjunctive antidepressant 
therapy in 2005, and deep brain stimulation (DBS). 
DBS has been approved for compassionate use 
in obsessive-compulsive disorder and is currently 
experimental for TRMD.3,4 In some severe cases, 
surgical interventions are used, including subcau-
date tractotomy, limbic leucotomy, anterior cap-
sulotomy, and anterior cingulotomy.5 Unlike VNS 
and DBS, these neurological surgeries involve cre-
ation of a lesion. In the case of a complete bilateral 
cingulotomy (as described here), this lesion would 
limit communication between the more anterior 
and posterior portions of the cingulum bundle. 
We describe the case of a TRMD patient whose 
depression did not respond to aggressive pharma-
cotherapy, psychotherapy, bilateral anterior cingu-
lotomy, or ECT, but which remitted when treated 
with VNS in combination with ECT. 
CASE REPORT
Ms M, a Caucasian woman, 53 years of age, 
had TRMD of 33 years duration, and posttraumatic 
stress disorder (PTSD) related to sexual trauma 
that occurred around 20 years of age. Her depres-
sion began in her early teens and resulted in 
multiple psychiatric hospitalizations and several 
serious suicide attempts during her early twen-
ties. She denied being depression-free for >30 
consecutive days, alternating between “severely 
depressed” and “mildly depressed” for her 
entire adult life. She had no history of psychosis 
or manic episodes. She reported limited anxiety 
symptoms, predominantly PTSD-related (recur-
rent flashbacks and avoidance), although she 
reported that these symptoms had not impaired 
her functioning during the previous 10 years. Her 
depressive symptoms were primarily character-
ized by low mood, anhedonia, anorexia, weight 
loss, helplessness, hopelessness, excessive guilt, 
and suicidal ideation. She had an extensive fam-
ily history of depression, including a brother who 
committed suicide. She denied use of illicit drugs 
but reported a history of alcoholism that was 8 
years in sustained remission. Her medical history 
was remarkable for hypothyroidism (controlled), 
fibromyalgia, epilepsy (controlled), and estro-
gen-replacement hormone therapy for oophorec-
tomy for uterine cancer. The patient began having 
seizures following a closed head trauma which 
occurred at 46 years of age (her depression pre-
ceded her epilepsy). She reported an average of 
2 seizures/year (tonic-clonic) from 46–53 years of 
age, and she reports that she does not recollect 
her depression being any worse after the seizures 
than before. 
Ms M’s pharmacotherapy treatment history for 
TRMD was extensive. Over the previous 30 years, 
she had been treated with various combinations of 
2–5 antidepressants and numerous augmentation 
agents. She had failed adequate dose-duration 
antidepressant trials with several different classes 
of antidepressant including selective serotonin 
inhibitors (citalopram, paroxetine, fluvoxamine, 
and escitalopram), tricyclic antidepressants (imip-
ramine, amitryptyline), serotonin-norepinephrine 
reuptake inhibitors (venlafaxine extended release, 
duloxetine), buproprion, nefazodone, as well as 
antidepressant augmentation trials with lithium, 
aripiprazole, and olanzapine. She had multiple 
courses of ECT (bilateral and unilateral) from 
1970–2006, with generally limited immediate ben-
efit and no sustained or long-term benefit. In 1981, 
she underwent bilateral anterior cingulotomy for 
TRMD, which had no effect on depressive symp-
toms. She attempted suicide on several occasions 
after the cingulotomy. In 1983 she underwent a 
course of bilateral ECT (10 treatments) with no 
response. Two years later, another course of 10 
bilateral ECT treatments also failed. 
With regards to history of Diagnostic and 
Statistical Manual of Mental Disorders, Fourth 
Edition axis II pathology: none of her outpatient 
records lists her as having an Axis II diagnosis. 
Two psychiatric hospitalizations (1999 and 2000) 
listed the diagnosis of “borderline personality dis-
order”; a subsequent hospitalization (2005) listed 
“rule out borderline personality disorder”. She 
underwent a Minnesota Multiphasic Personality 
Inventory assessment in 2000, while hospitalized, 
which concluded: “nonspecific findings—marked 
anxiety, neediness, feelings of inadequacy, and 
ruminations over past trauma.”
In late 2005 and early 2006 Ms. M failed another 
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three month antidepressant combination trial: 
duloxetine (90 mg QD) combined with quetiapine 
(300 mg HS) and lithium (300 mg TID), as well as 
topiramate (200 mg QHS) for epilepsy. In March 
2006, having failed an extensive list of antide-
pressant and mood stabilizers, Ms M underwent 
implantation of a VNS device for TRMD. Her previ-
ously described medications (ie, duloxetine, que-
tiapine, lithium, and topiramate) were unchanged. 
VNS was initially ineffective, with her depression 
(suicidal thoughts) resulting in a psychiatric hos-
pitalization in May 2006. While in hospital, with 
VNS ongoing, she underwent three unilateral ECT 
treatments (VNS was temporarily deactivated 
only during the interval in which she received the 
ECT treatments), with considerable acute antide-
pressant benefit. At discharge, medications were 
duloxetine (60 mg QD), temazepam (15 mg QHS), 
and quetiapine (400 mg QHS). 
After discharge, the patient experienced con-
tinued improvement in her depressive symptoms. 
In June of 2006, she reported that her depression 
was “much better,” and that her core primary 
symptoms (anhedonia, decreased energy, hope-
lessness, helplessness, suicidal ideation) were 
“gone.” At this time, quetiapine was discontinued 
and zolpidem (for sleep) was added; otherwise, 
only limited dose adjustments occurred dur-
ing the subsequent months. Three and one-half 
years later, she remains depression-free with no 
residual depressive symptoms. During a recent 
(December 2009) assessment, she scored 4 on the 
Montgomery-Åsberg Depression Rating Scale, 
which is consistent with depression remission. 
At that time, she reported stable mood, good 
sleep and appetite, social activity, good energy, 
and motivation. In addition to VNS, her medica-
tions were duloxetine (60 mg PO QD), temazepam 
(15 mg QHS), and zolpidem (10 mg QHS). She 
also continued to participate in weekly cognitive 
behavioral psychotherapy sessions, which began 
five years ago. Additionally, she reports she has 
not had any seizures following the implant of her 
VNS device. 
A high resolution computed tomography (CT 
scan; Figure 1), acquired using a General Electric 
LightSpeed VCT 64-Slice CT scanner (30 cm FOV, 
no gantry tilt, 1024 x 1024 matrix, 1.5 mm slice 
thickness) was obtained following placement of 
VNS. Review of the CT scan and comparison to 
standard brain atlases demonstrates a bilateral 
lesions (from the 1981 cingulotomy surgery) in the 
mid-portion of the cingulate gyrus with complete 
obliteration of the structure in the superior inferior 
and medial lateral dimensions. 
DISCUSSION
This case report highlights a woman, now 56 
years of age, with a lifelong history of profound 
and debilitating TRMD characterized by numer-
ous failed antidepressant medication trials, failed 
ECT trials (both before and after cingulotomy), 
and failed bilateral anterior cingulotomy, who has 
experienced sustained remission of her TRMD 
after VNS and a brief course (3 treatments) of ECT. 
This case also highlights the potential synergis-
Review Article
FIGURE 1.
Three different high resolution CT views of the cingulotomy lesion*
Panel A: Coronal view of the cingulotomy lesion demonstrating the near-complete superior-inferior ablation of the cingulate gyrus. Panel B: sagittal view of the medial surface 
of the left hemisphere. Note the near complete transection of the cingulate extending from the superior surface to the corpus callosum. Panel C: An oblique view leaving skull 
in place with lesion area highlighted in green. CT images acquired using a General Electric LightSpeed VCT 64-Slice CT scanner (30 cm FOV, no gantry tilt, 1024 x 1024 matrix, 
1.5 mm slice thickness). CT images created using the Dextroscope® platform (Volume Interactions, Bracco Industries, Buckinghamshire, UK). 
* Arrows denote the edges of cingulotomy lesion. 
Conway CR, Gebretsadik MD, Bucholz RD. CNS Spectr. 2011.
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tic effect of VNS and ECT and allows for consider-
ation of the neural pathways that may be essential 
for a VNS response in TRMD, including the fact 
that a completely transected anterior cingulate did 
not prevent an antidepressant response to VNS. 
Several articles describe the concomitant use of 
ECT with VNS.6-8 ECT is not contraindicated in VNS, 
but it is recommended that the device be deacti-
vated during the ECT procedure to avoid poten-
tial complications involving cardiac or pulmonary 
side effects.6 Some reports have suggested that 
ECT and VNS may have a synergistic antidepres-
sant effect.7,8 Our group has observed a similar anti-
depressant synergistic effect between VNS and ECT 
in 3 cases as well (patients with lifelong histories of 
requiring recurrent ECT, no longer requiring ECT as 
frequently or requiring fewer ECT with the addition 
of VNS). Sharma and colleagues8 described two 
patients (unipolar, bipolar depression) for whom 
ECT had previously been unsuccessful. In both 
patients, VNS, was initially unsuccessful until ECT 
was reintroduced. It is also possible, in the case 
described above, that the ECT simply coincided 
with the patient’s response to VNS. 
Demonstrating a direct causal relationship 
between our patient’s sustained depression remis-
sion and VNS is not possible. Her history, however, 
lacked any sustained antidepressant response 
to any treatment. Before she received VNS, ECT 
had not previously elicited a response. Although 
some patients may experience an acute antide-
pressant response with only 3 ECT treatments, the 
typical recommended effective “dose” of ECT, in 
order to sustain the antidepressant response, is >3 
treatments.9,10 Her initial early response to ECT, as 
well as her sustained euthymia suggest that VNS 
may have played a synergistic role with ECT. Ms. 
M is currently depression-free, and has been for 
4 years. Before receiving VNS, she reported no 
depression-free period >1 month over her entire 
life. Sackeim and colleagues11 studied the effective-
ness of ECT in TRMD in which ECT had been dis-
continued, and they reported a very high relapse 
rate (~70% at 1 year). 
VNS has well-established efficacy in treat-
ment-resistant epilepsy. Additionally, there is a 
clear association between epilepsy and depres-
sion; hence it is possible that the patient’s par-
tially-controlled epilepsy was contributing to her 
depression.12 However, her depressive symptoms 
(including hospitalizations and suicide attempts) 
clearly preceded her traumatic epilepsy onset. It 
is noteworthy that in addition to her depression 
resolution, the patient also reports no further sei-
zures following VNS implantation. 
This case report may provide some key insights 
into the critical neuroanatomical network compo-
nents “required” for successful VNS treatment 
in TRMD. The mechanism of action of VNS in 
TRMD, as in epilepsy, is incompletely understood. 
There is evidence that the effects of VNS on the 
brain systems associated with mood are medi-
ated both through primary brainstem nuclei pro-
jections (dorsal raphe, locus ceruleus, nucleus 
tractus solitarius) and limbic system and direct 
cortical pathways.13,14 Current models of depres-
sion hypothesize that depression represents a 
dysregulation of several interconnected structures 
in the frontal and limbic circuitry.15-17 Key struc-
tures in this network include the prefrontal cortex 
(medial, orbital, and dorsolateral), the amygdala, 
the cingulate cortex, the hippocampus, striatum, 
dorsal thalamus, and the hypothalamus. Many of 
these structures intersect with the upstream affer-
ent pathway of the vagus (Figure 2). 
The cingulate cortex, fully transected in Ms. M’s 
case, is considered a pivotal region in depression 
neuroimaging studies. Visual inspection of the high 
resolution CT scans (Figure 1) demonstrates that 
the patient’s cingulate gyrus was transected at the 
junctional region of the dorsal anterior cingulate 
and the mid-cingulate. The transection occurred 
well forward of the posterior cingulate cortex. 
The cingulate (and underlying cingulum bundle) 
is a critical structure in mood disorders. Structural 
neuroimaging studies have demonstrated a reduc-
tion in gray matter volume in the left subgenual 
anterior cingulate in individuals with depression.18-
20 Functional neuroimaging studies of the subgen-
ual anterior cingulate cortex (Brodmann’s area [BA] 
25) in depression have also shown this region to 
be hypometabolic compared with non-depressed 
controls.20 Other studies have demonstrated that 
when corrected for the volume loss occurring in 
this region with depression, BA 25 is actually hyper-
metabolic compared with nondepressed controls.21 
Further, numerous treatment modalities, includ-
ing medications,22 DBS,3 and sleep deprivation23 
have demonstrated decreased metabolism of BA 
25. More dorsal regions of the cingulate also have 
been identified as involved in depression. Studies 
have found that the dorsal anterior cingulate (dor-
sal to the corpus callosum and posterior to the genu 
of the corpus callosum) also undergoes change 
with depression: positron-emission tomography 
imaging studies assessing antidepressant and DBS 
Review Article
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antidepressant response demonstrate increased 
activation of this region.24,25 
How might activation of the left vagus affect the 
fronto-limbic mood circuitry? Upstream vagal pro-
jections synapse with anterior components of these 
fronto-limbic circuits: most of the upstream affer-
ent fibers of the vagus travel via the nucleus trac-
tus solitaries (NTS).13 Fibers from the NTS project 
to the central nucleus of the amygdala as well as 
the nucleus accumbens. Additionally, animal mod-
els demonstrate the NTS, synapsing through the 
parabrachial nucleus, also send projections to the 
thalamus, the amygdala (particularly the central 
nucleus of the amygdala, but also the basolateral 
and other amygdalar nuclei), the anterior insula, 
and infralimbic cortex, lateral prefrontal cortex, 
and other cortical regions.13,26 Of note, the predomi-
nance of upstream vagal afferent pathways target 
regions in the anterior/temporal portions of these 
circuits (ie, amygdala, nucleus accumbens, insula, 
and prefrontal cortex). The connections between 
these regions would have been spared in the cin-
gulotomy described in this case report (location of 
surgical lesion depicted in Figure 3). 
Neuroimaging studies of VNS in TRMD dem-
onstrate that most of the acute effects of VNS in 
TRMD occur in anterior and temporal regions.27-30 
These regions include the anterior cingulate, the 
insular region, lateral and medial prefrontal cor-
tex, and orbitofrontal cortices. 
Given the known neuroanatomy and evidence 
from neuroimaging studies, two distinct (though 
by no means exclusive) methods by which VNS 
acts on the fronto-limbic mood circuitry emerge: 
amygdalar and lateral orbital-insular synaptic 
pathways. The amygdala is known to have exten-
sive cortical projections, including the rostral 
insula and temporal pole; however, the strongest 
of these connections are with the medial prefron-
tal cortex rostral and ventral to the genu of the 
corpus callosum.17 Similarly, vagal projections to 
the lateral orbital cortex (and adjacent anterior 
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FIGURE 2.
Intersection between the affarent vagal pathway and the frontolimbic model of 
depression15
The model emphasizes how orbital and MPFC dysfunction leads to disinhibition of neural transmission through the amygdala (efferent paths from amygdala in red). Animal and 
human neuroimaging studies have determined that the upstream pathways of the vagus have multiple intersections with the brain regions in this model (depicted by asterisks 
alongside the structure). The majority of these regions are anteriorly positioned in the brain.
Figure adapted from Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depres-
sion. Brain Struct Funct. 2008;213(1-2):93-118.
BNST=bed nucleus of the stria terminalis; Basal N=basal nucleus of the amygdala; Central N=central nucleus of the amygdala; PAG=periaqueductal gray;  PVN=peraventricular 
nucleus of the hypothalamus; VTA=ventral tegmental area; MPFC=medial prefrontal cortex. 
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insular regions), which likely interact with medial 
prefrontal regions, may be another mechanism 
by which VNS acts in TRMD. In both instances, 
these mechanisms of action seem to have minimal 
involvement with the posterior limbic/paralimbic 
circuitry and would not be affected by a bilateral 
cingulotomy.
Understanding the anatomy of the cingulate 
gyrus and underlying white matter (cingulum bun-
dle) and the mechanism by which this structure 
integrates with other components of the fronto-
limbic mood network may provide insights into 
the reasons for the success of VNS in an individual 
with a complete bilateral cingulotomy. 
The anatomy and interconnections of fibers 
making up the cingulate gyrus are very complex 
and beyond the scope of this case report. Mufson 
and Pandya31 used an autoradiographic tracer 
injection studies in Rhesus monkeys to analyze 
the constituent white matter components of the 
cingulum bundle. They found that most cingulum 
fibers arise from the thalamus, the cingulate cor-
tex itself, and association areas (Figure 3). Fibers 
from all three origins project both rostrally and 
caudally. Interestingly, fibers arising from both the 
anterior and posterior portions of the cingulate 
cortex projected into prefrontal cortex; however, 
only fibers from the anterior portion (BA 24; Figure 
3, panel A) project into the insula and amygdala. 
In contrast, fibers originating from the posterior 
cingulate cortex (BA 23; Figure 3, panel B) did not 
project to these structures.31 These tracer studies 
suggest that the principal direct communication 
between cingulate cortex and other central com-
ponents (eg, amygdala) of the frontal-limbic cir-
cuitry implicated in mood disorders predominantly 
involves the more anterior cingulate regions. 
On the basis of this case report, it appears that 
direct communication between the posterior and 
anterior cingulate is not necessary for VNS to be 
efficacious in TRMD. Unlike DBS or VNS, a cin-
gulotomy involves physically lesioning neuronal 
pathways: a complete bilateral transection of the 
cingulate cortex would likely cut at least much if 
not all of the synaptic communication between 
anterior and posterior components of the “default 
mode system” (medial and dorsal prefrontal cor-
tex and posterior cingulate cortex).32  Recent stud-
ies33 suggest individuals with depression have 
problems “shifting out” of the default mode sys-
tem when challenged. Because the default mode 
system has been associated with self-referential 
function, it can be suggested that persistent activ-
ity in the system may be associated with rumina-
tion on self-related, possibly negative thoughts. 
CONCLUSION
To our knowledge, this study is the first reported 
case of a patient with a failed cingulotomy for 
TRMD who subsequently experienced an antide-
pressant response to VNS. Based on the computed 
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FIGURE 3.
Regional course of the cingulum fibers 
in the anterior and posterior cingulate 
cortex (Rhesus monkey)31
The red vertical line represents approximate anterior margin of the cinguloto-
my lesion in this case. Using autoradiographic tracer injection studies Mufson 
and Pandya31 were able to analyze the constituent white matter components 
of the cingulum bundle. They found fibers arising from both the anterior and 
posterior portions of the cingulate cortex projected into prefrontal cortex; 
however, only fibers from the anterior portion (BA 24; Panel A) projected into 
the insula and amygdala. In contrast, fibers originating from the posterior 
cingulate cortex (BA 23; Panel B) did not project to these structures. These 
tracer studies suggest that the principal direct communication between 
cingulate cortex and other central components (eg, the AMG) of the frontal-
limbic circuitry implicated in mood disorders predominantly involves the more 
anterior cingulate regions, which would not be affected by the cingulotomy 
lesion (anterior margin of lesion depicted with dotted vertical line). 
AMG=amygdala; CC=corpus callosum; CING BUN=cingulum bundle; 
CING SUL=cingulate sulcus; PF=prefrontal cortex; INS=insula; p=pons; 
PRH=parahippocampal gyrus; m=medulla; TH=thalamus; BA=Brodmann’s 
area.
Conway CR, Gebretsadik MD, Bucholz RD. CNS Spectr. 2011.
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tomography confirmed, near-complete oblitera-
tion of the bilateral cingulate, this case suggests 
an intact cingulum (in the anterior-posterior axis) 
is not necessary to respond to VNS. Considering 
that the most aggressive of treatments had failed 
for Ms. M’s TRMD, this case study highlights the 
potential efficacy of VNS in very treatment resis-
tant clinical depression and emphasizes the need 
for further studies to determine the mechanism of 
action of VNS in TRMD. CNS
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